The global cancer therapeutics market is expected to grow at growth rate of 10.0% to reach USD 186.3 billion by 2025. This comprehensive study reveals the market estimate numbers for different market segments. Along with that, the study covers qualitative insights, strategic benchmarking and thorough competitive landscaping in the report spreading over 180 pages.

Cancer is characterized by the abnormal proliferation of cells beyond their usual boundaries. This disease is one of the most prevalent chronic conditions, affecting millions of population worldwide every year. For example, as per the World Health Organization (WHO), more than 9.6 million patients died due to cancer in 2018 across the globe. The organization has also mentioned that the number of new cancer cases is projected to rise by 70% over the next 2 decades. Due to constant rising in cancer incidences, research activities to develop new and effective therapeutics has increased significantly. It is justified by the sharp increase in the number of pipeline therapeutics. According to an article published by the American Cancer Society (2017), the pipeline of oncology drugs has expanded by 60% during the past decade. In addition, favorable government initiatives would, in turn, support the industry growth significantly. For example, Conference Series Ltd. is engaged in organizing numerous Oncology & Cancer Conferences. This organization has hosted more than 600 conferences, 1200 symposiums, and 1200 plus workshops on cancer-related topics. However, challenges encountered during the clinical trials for developing cancer therapeutics is expected to hamper the industry growth to some extent.

Request exclusive PDF sample copy of the report:
https://www.analystviewmarketinsights.com/request_sample/av132/

Key Takeaways:

•Of the different types, blood and breast cancers are accounted for the majority of revenue share. Increasing incidences of these cancers drive the segment growth. According to the Leukemia & Lymphoma Society (LLS), every three minutes, one person is diagnosed with a blood cancer in the U.S.
•However, prostate cancer is anticipated to grow with the fastest CAGR of 12.6% during the forecast period. Advancements in proteomic technologies coupled with improvements in screening and diagnosis techniques will support the segment growth.
•Chemotherapy accounted for the highest revenue share, accounted for more than 45% share throughout the study period. Its potential molecular genetics assessment, low side effects and proven efficacy back up the growth.
•Agents like alkylating agents, anti-metabolites, and anti-microtubule agent are commonly used for the chemotherapy treatment
•We analyzed that by 2020, most of the oncology drugs will be available for multiple indications. A new wave of cancer therapy is sweeping the industry landscape and offering excitement and hope among cancer drug manufacturers.
•Lots of efforts are made by many researchers to develop cancer therapeutics for multiple indications. For example, of 88 cancer therapeutics marketed in 2014, approximately 40 were for single indications and more than 48 were for multiple indications. This new strategy, would, in turn, amplify the need for end-users.
•North America accounted for significant revenue share due to a continuous increase in the patient numbers in the U.S. As per the National Cancer Institute (NCI), in 2016, around 1,685,000 new cancer cases were recorded in the U.S. and 595,690 patients died from the disease.
•In addition, a launch of novel therapeutics such as Xtandi (enzalutamide), Zytiga (abiraterone acetate) and Xofigo set a healthy platform for the regional growth and development
•This fragmented industry is characterized by the presence of a large number of small scale and large scale players. F. Hoffmann-La Roche emerged as a key player, contributing 17.03% share of the global market owing to the strong performance of company’s blockbuster drug Avastin and Herceptin. In 2015, the company registered USD 6,631.6 and USD 6,486.7 from Avastin and Herceptin respectively.
•Whereas, companies namely Novartis, Amgen, Inc., Johnson and Johnson, and Eli Lilly and Company captured significant market share. New product launch and strategic collaborations helped these players to sustain their market position
•In April 2018, Eli Lilly and Company announced positive phase III result of Cyramza (Ramucirumab) for the treatment of patients with hepatocellular carcinoma (HCC), a type of liver cancer.

Browse full research highlight with in-depth ToC on “Cancer Therapeutics Market, By Types and Geography – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025” at

https://www.analystviewmarketinsights.com/report-highlight-cancer-therapeutics-market-132/

The scope of this report covers the market by its major segments, as follows:
MARKET, BY TYPES
Prostate Cancer
Blood Cancer
Lung Cancer
Skin Cancer
Gastrointestinal Cancer
Breast Cancer
Others

MARKET, BY THERAPY
Chemotherapy
Hormonal
Immunotherapy
Targeted Therapy
Others

MARKET, BY REGION
North America
U.S.
Canada
Europe
Germany
France
Rest of Europe
Asia Pacific
India
China
Rest of APAC

Rest of the World
Middle East and Africa
Latin America

Key players profiled in this report with special attention on competitive landscape includes, (can be further customized to include additional 10 profiles):
F. Hoffmann-La Roche
Novartis
Johnson and Johnson
Pfizer Inc.
Sanofi Aventis
Merck & Co., Inc.
GlaxoSmithKline plc
Eli Lilly and Company

Key Question Answered:
What are the key market trends, drivers, barriers, opportunities and recommendations?
What will the market size be from 2014 to 2025 and expected growth rate?
What is the revenue share of cancer therapeutics market, by types, by therapy, and by different geographies?
Who are the largest revenue contributor as well as fastest growing category for respective industry segments?
Who are the key vendors in Global Cancer Therapeutics Market space?
What are the strategies adopted by key vendors to expand their market presence?
What is the revenue share of key players operating in this market (2017)?
Please note that preparing of customized report catering to a particular region or country is also possible within quicker timeframe as we follow bottom-up research methodology

Value Proposition:
•We are committed to provide valuable insights to our clients in order to help them take strategic decisions and in turn influencing revenue growth. The proposed study answers several important questions for stakeholders, primarily which industry segments to focus on in the next three to five years for prioritizing investments
•The proposed report presents a macro and micro-level outlook regarding the industry. Thus, it becomes easy for our clients to perceive the business landscape and take a glimpse of their own standing in it.
•A thorough analysis of relevant statistical data to estimate the market paradigms
•Exceptional understanding of the region and country-specific markets. The report will answer some of the toughest questions regarding the market shares, sizes, forecasts segmentations, and growth specific to the countries.
•Well-designed strategic framework analyzes the market movements including regional expansion, mergers & acquisitions, and new product developments

Find out more by getting in touch: https://www.analystviewmarketinsights.com/get-in-touch/

About Us
AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends for various industries such as Healthcare, Bulk Chemicals, Semiconductors, Electronics, and Foods and Beverages.

Contact Us
Mr. Jose (Press & Marketing Manager)
Corporate Sales, USA
AnalystView Market Insights
Email: [email protected]
Web: www.analystviewmarketinsights.com